all Press Releases

  • 5/2/16 8:00 am EDT
    RALEIGH, N.C.--(BUSINESS WIRE)--NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that it filed a voluntary petition under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (the “Court”). In connection with its decision to seek Chapter 11 protection, NephroGenex has retained the investment banking firm of Casselmore...
  • 2/24/16 9:20 am EST
    RALEIGH, N.C.--(BUSINESS WIRE)--NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that its Board of Directors has made a determination to pause the clinical program of the Company’s product candidate oral Pyridorin® for the treatment of diabetic nephropathy, effect a restructuring of its operations, and implement a strategic transaction. The Board of Directors made this determination inmore...
  • 1/27/16 8:00 am EST
    RALEIGH, N.C.--(BUSINESS WIRE)--NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that CEO and President Pierre Legault will present a corporate overview of the Company and meet with investors at the 18th Annual BIO CEO & Investor Conference. The presentation will take place on Monday, February 8 at 3:00 pm EST at The Waldorf Astoria in New York City. About NephroGenex, Incmore...
  • 1/21/16 4:05 pm EST
    RALEIGH, N.C.--(BUSINESS WIRE)--NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that the independent Data and Safety Monitoring Board (DSMB) for the Company’s pivotal Phase 3 study of oral Pyridorin® for the treatment of diabetic nephropathy has completed the second, pre-planned six-month safety review and has unanimously recommended that the study continue without modification. Basedmore...
  • 1/6/16 8:00 am EST
    RALEIGH, N.C.--(BUSINESS WIRE)--NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that CEO and President Pierre Legault will present a corporate overview of the Company at two upcoming healthcare conferences in January. The Company will also meet with members of the investment community while in San Francisco during the week of January 11. Presentation Details:more...
  • 1/5/16 8:00 am EST
    RALEIGH, N.C.--(BUSINESS WIRE)--NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the appointment of leading experts in nephrology to its newly formed Scientific Advisory Board (SAB). The SAB will serve as a strategic resource to NephroGenex as it continues to develop the Company’s novel drug candidates to treat kidney disease. Composition of NephroGenex’s Scientificmore...
  • 12/14/15 8:00 am EST
    RALEIGH, N.C.--(BUSINESS WIRE)--NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug (IND) application for clinical studies with intravenous Pyridorin® for the treatment of acute kidney injury. Acute kidney injury (AKI) is a serious medical condition characterized by an abrupt lossmore...
  • 11/11/15 4:05 pm EST
    RALEIGH, N.C.--(BUSINESS WIRE)--NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and business highlights for the third quarter ended September 30, 2015. “During the third quarter of 2015, we continued to make progress in advancing our Phase 3 study of oral Pyridorin for the treatment of diabetic nephropathy, adding new clinical sites and increasing themore...
  • 11/4/15 4:15 pm EST
    RALEIGH, N.C.--(BUSINESS WIRE)--NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced successful results from a preclinical toxicity study of intravenous Pyridorin® being developed to treat acute kidney injury (AKI). Male and female Sprague-Dawley rats given 50, 100 and 200 mg/kg of Pyridorin (Pyridoxamine Dihydrochloride) once daily by intravenous infusion over 30 minutes for sevenmore...
  • 11/4/15 8:00 am EST
    RALEIGH, N.C.--(BUSINESS WIRE)--NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, will report financial results for the quarter ended September 30, 2015 on Wednesday, November 11, after the U.S. financial markets close. The Company will host a conference call and webcast the following day, Thursday, November 12, at 8:30 a.m. EST, to review third quarter results and provide an update on its PIONEERmore...